Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

Lancet Infectious Diseases

Volumn 3, Issue 11, 2003, Pages 685-702

  Eggimann, Philippe ^a   Garbino, Jorge ^b   Pittet, Didier ^c  

^a Infection Control Program   (Switzerland)

^b Division of Infectious Diseases   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CEPHALOSPORIN DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NYSTATIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

CANDIDA; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CRITICAL ILLNESS; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DRUG SENSITIVITY; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION PREVENTION; INTENSIVE CARE UNIT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0242323689     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00801-6     Document Type: Review

References (177)

1. Gray LD, Roberts GD. Laboratory diagnosis of systemic fungal diseases. Infect Dis Clin North Am 1988; 2: 779-803.
2. Armstrong D. Overview of innasive fungal infections and clinical presentation. Baillière's Clin Infect Dis 1995; 2: 17-24.
3. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526-30.
4. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am 2002; 16: 793-820.
5. Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-45.
6. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
7. Debusk CH, Daoud R, Thirumoorthi MC, Wilson FM, Khatib R. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994; 26: 697-703.
8. Leleu G, Aegerter P, Guidet B, for Collège des Utilisateurs de Base de Données en Réanimation. Systemic candidiasis in intensive care units: a multicenter matched-cohort study. J Critical Care 2002; 17: 168-75.
9. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
10. Girmenia C, Martino P. Fluconazole and the changing epidemiology of candidemia. Clin Infect Dis 1998; 27: 232-34.
11. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis by different Candida species. Clin Infect Dis 1997; 24: 1122-28.
12. Wingard JR, Merz WG, Rindali MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-77.
13. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-85.
14. Louria DB. Pathogenesis of candidiasis. Antimicrob Agents Chemother 1965; 5: 417-26.
15. Cohen R, Roth FJ, Delgado E, Ahearn DG, Kalser MH. Fungal flora of the normal human small and large intestine. N Engl J Med 1969; 280: 638-41.
16. Klotz SA, Drutz DJ, Zajic JE. Factors governing adherence of Candida species to plastic surfaces. Infect Immun 1985; 50: 97-101.
17. Freydiere AM, Guinet R, Boiron P. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med Mycol 2001; 39: 9-33.
18. Buchaille L, Freydiere AM, Guinet R, Gille Y. Evaluation of six commercial systems for identification of medically important yeasts. Eur J Clin Microbiol Infect Dis 1998; 17: 479-88.
19. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
20. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997; 24: 235-47.
21. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
22. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. J Clin Microbiol 2002; 40: 1298-302.
23. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-37.
24. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-17.
25. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequcnces. Lancet Infect Dis 2002; 2: 73-85.
26. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405-16.
27. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 (suppl I): 119-28.
28. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 2001; 45: 52-59.
29. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39: 40-44.
30. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-49.
31. Masia CM, Gutierrez RF. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550-63.
32. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-58.
33. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole and voriconazole among isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001; 39: 3254-59.
34. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489-95.
35. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeast: approved standard. Washington DC, USA. NCCLS document M27-A, 1997.
36. Pfaller MA, Rex JH, Rinaldi MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997; 24: 776-84.
37. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-58.
38. Chryssanthou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the sensititre yeast. One colorimetric antifungal panel with the NCCLS M27-A reference method. J Clin Microbiol 2001; 39: 4181-83.
39. Morace G, Amato G, Bistoni F, et al. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards m27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 2002; 40: 2953-58.
40. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-44.
41. British Society for Antimicrobial Chemotherapy. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20: 522-28.
42. Edwards JEJ, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
43. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-16.
44. Buchner T, Fegeler W, Bernhardt H, et al. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis 2002; 21: 337-52.
45. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
46. Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
47. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 1995; 274: 639-44.
48. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care (EPIC) Study. Eur J Clin Microbiol Infect Dis 1996; 15: 281-285.
49. Beck-Sague CM, Jarvis W. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51.
50. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22 (suppl 2): 89-94
51. Jarvis WR, Martone W. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 (suppl A): 19-24.
52. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999; 27: 887-92.
53. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21: 510-15.
54. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
55. National Nosocomial Infections Surveillance (NNIS) system report. Data summary from January 1992-June 2001. Am J Infect Control 2002; 29: 404-21.
56. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70.
57. Richet H, Andremont A, Roux P, De Champs C, Esnalut Y. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002; 8: 405-12.
58. Slavin MA. The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 2002; 49 (suppl 1): 3-6.
59. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 1998; 36: 3455-59.
60. Doczi I, Dosa E, Hajdu E, Nagy E. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol 2002; 51: 677-81.
61. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends 1991-2000. Clin Infect Dis (in press)
62. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 86-89S.
63. Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R. Epidemiology of Candidemia-a nationwide survey in Israel. Infection 2000; 28: 26-29.
64. Tortorano A, Biraghi E, Astolfi A, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51: 297
65. Bregenzer T, Evison-Eckstein AC, Frei R, Zimmerli W. Clinical aspects and prognosis of candidemia, a 6-year retrospective study. Schweiz Med Wochenschr 1996; 126: 1829-33.
66. Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care center. Eur J Clin Microbiol Infect Dis 2000; 19: 602-07.
67. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002; 45: 141-45.
68. Voss A, Kluytmans JA, Koeleman JG, et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 1996; 15: 909-12.
69. Garbino J, Kolarova L, Rohner P, Lew D, Pincha P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002; 81: 425-33.
70. Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002; 21: 767-74.
71. Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254-57.
72. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995; 155: 1177-84.
73. Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996; 95: 19-28.
74. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001; 33: 177-86.
75. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-85.
76. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessement of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
77. Voss A, le Noble JL, Verduyn LF, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997; 25: 8-11.
78. Petri MG, König J, Moeckc HP, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 1997; 23: 317-25.
79. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of III cases. Pediatr Infect Dis J 1998; 17: 504-08.
80. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991; 13: 211-15.
81. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
82. MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998; 26: 642-45.
83. Krcmery VJ, Kovacicova G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 2000; 36: 7-11.
84. Mathews MS, Samuel PR, Suresh M. Emergence of Candida tropicalis as the major cause of fungaemia in India. Mycoses 2001; 44: 278-80.
85. Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 2001; 44: 446-49.
86. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-46.
87. Wingard JR. Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-25.
88. Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001; 45: 2129-33.
89. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-79.
90. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7: 646-55.
91. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45.
92. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada and South America for the SENTRY program. J Clin Microbiol 1998; 36: 1886-89.
93. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-51.
94. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis 1999; 35: 19-25.
95. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40: 852-56.
96. Nguyen MH, Peacock JE, Jr., Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23.
97. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20: 571-75.
98. Karlowsky JA, Zhanel GG, Klym KA, Hoban DJ, Kabani AM. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997; 29: 5-9.
99. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J 2000; 19: 319-24.
100. St-Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: result of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949-53.
101. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
102. Nucci M, Silveira MI, Spector N, et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998; 27: 107-11.
103. Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281-86.
104. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002; 21: 209-11.
105. Zanetti G, Calandra T, de Muralt B, Bille J, Glauser MP. Candida fungemia. Schweiz Med Wochenschr 1989; 119: 1213-18.
106. Krcmery V, Fric M, Pisarcikova M, et al. Fungemia in neonates: report of 80 cases from seven university hospitals. Pediatrics 2000; 105: 913-14.
107. Samra Z, Bishara J, Ashkenazi S, et al. Changing distribution of Candida species isolated from sterile and nonsterile sites in Israel. Eur J Clin Microbiol Infect Dis 2002; 21: 542-45.
108. Krcmery VCJ, Babela R. Candidemia in the surgical intensive care unit. Clin Infect Dis 2002; 34: 1537-38.
109. Oude LA, Donnelly JP, Meis JF, van der Meer JW, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003; 22: 43-48.
110. Chakrabarti A, Chander J, Kasturi P, Panigrahi D. Candidaemia: a 10-year study in an Indian teaching hospital. Mycoses 1992; 35: 47-51.
111. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30.
112. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995; 155: 2429-35.
113. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964-72.
114. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16: 337-45.
115. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-29.
116. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-28.
117. Goldman M, Pottage JCJ, Weaver DC. Candida krusei fungemia. Report of 4 cases and review of the literature. Medicine 1993; 72: 143-50.
118. Vazquez JA, Sobel JD, Peng G, et al. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Clin Infect Dis 1999; 28: 1025-31.
119. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-54.
120. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-200.
121. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-58.
122. Wright WL, Wenzel RP. Nosocomial Candida. Epidemiology, transmission, and prevention. Infect Dis Clin North Am 1997; 11: 411-25.
123. Voss A, Honis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994; 32: 975-80.
124. Samonis G, Gikas A, Anaissie EJ, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993; 37: 51-53.
125. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969; 1: 598-99.
126. Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985; 23: 265-73.
127. Solomkin JS. Pathogenesis and management of Candida infection syndromes in non-neutropenic patients. New Horiz 1993; 1: 202-13.
128. Gianotti L, Alexander JW, Fukushima R, Childress CP. Translocation of Candida albicans is related to the blood flow of individual intestinal villi. Circ Shock 1993; 40: 250-57.
129. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-53.
130. Ekenna O, Sherertz RJ, Bingham H. Natural history of bloodstream infections in a burn patient population: the importance of candidemia. Am J Infect Control 1993; 21: 189-95.
131. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 1993; 168: 195-201.
132. Pfaller MA, Messer SA, Houston A, et al. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998; 31: 289-96.
133. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990; 28: 2733-38.
134. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit. Diagn Microbiol Infect Dis 1995; 21: 191-94.
135. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33: 1959-67.
136. Pittet D, Monod M, Filthuth I, Frenk E, Suter PM, Auckenthaler R. Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections. Am J Med 1991; 91: 256-263S.
137. Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26: 429-32.
138. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay NK, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177-84.
139. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990; 8: 280-86.
140. Bross J, Talbot GH, Maislin G, Hurwits S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87: 614-20.
141. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-48.
142. Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987; 6: 190-96.
143. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
144. Botas CM, Kurlat I, Young SM, Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 1995; 95: 883-87.
145. Garbino J, Lew PD, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients. A randomized, double-blind, placebo-controlled trial in SDD-treated patients. Intensive Care Med 2002; 28: 1708-17.
146. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of candida in intraperitoneal infections. Surgery 1980; 88: 524-30.
147. Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122: 147-51.
148. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of candida isolated from peritoneum in surgical patients. Lancet 1989; 2: 1437-40.
149. Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20: 1119-24.
150. Slotman GJ, Shapiro E, Moffa SM. Fungal sepsis: multisite colonization versus fungemia. Am Surg 1994; 60: 107-13.
151. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
152. Sandven P, Qvist H, Skovlund E, Giercksky KE. Significance of candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30: 541-47.
153. Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal colonization with yeast species and candida septicemia in very low birth weight infants. Mycoses 1990; 33: 20-23.
154. Gross PA, DeMauro PJ, Van Antwerpen C, Wallenstein S, Chiang S. Number of comorbidities as a predictor of nosocomial infection acquisition. Infect Control Hosp Epidemiol 1988; 9: 497-500.
155. Reef SE, Lasker BA, Butcher DS, et al. Nonperinatal nosocomial transmission of Candida albicans in a neonatal intensive care unit: prospective study. J Clin Microbiol 1998; 36: 1255-59.
156. Klempp-Selb B, Rimek D, Kappe R. Karyotyping of Candida albicans and Candida glabrata from patients with Candida sepsis. Mycoses 2000; 43: 159-63.
157. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg 1999; 134: 657-64.
158. Solomkin JS, Flohr AB, Simmons RL. Indications for therapy for fungemia in postoperative patients. Arch Surg 1982; 117: 1272-75.
159. Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine 1993; 72: 137-42.
160. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-34.
161. Brassart D, Woltz A, Golliard M, Neeser JR. In vitro inhibition of adhesion of Candida albicans clinical isolates to human buccal epithelial cells by Fuc alpha 1-2Gal beta-bearing complex carbohydrates. Infect Immun 1991; 59: 1605-13.
162. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2002; 13: 122-43.
163. Odds EC. Switch of phenotype as an escape mechanism of the intruder. Mycoses 1997; 40 (suppl 2): 9-12.
164. Berman J, Sudbery PE. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet 2002; 3: 918-30.
165. Soll DR. Candida commensalism and virulence: the evolution of phenotypic plasticity. Acta Trop 2002; 81: 101-10.
166. Sendid B, Tabouret M, Poirot JL, Mathieu D, Fruit J, Poulain D. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999; 37: 1510-17.
167. Yera H, Sendid B, Francois N, Camus D, Poulain D. Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 2001; 20: 864-70.
168. Chen SC, Halliday CL, Meyer W. A review of nucleic acid-based diagnostic tests for systemic mycoses with an emphasis on polymerase chain reaction-based assays. Med Mycol 2002; 40: 333-57.
169. Rogers PD, Barker KS. Evaluation of differential gene expression in fluconazole-susceptible and resistant isolates of Candida albicans by cDNA microarray analysis. Antimicrob Agents Chemother 2002; 46: 3412-17.
170. Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101: 1302-09.
171. Dubau B, Triboulet S, Winnock S. Utilisation pratique de l'index de colonisation. Ann Fr Anesth Reanim 2001; 20: 418-20.
172. Chabasse D. Intérêt de la numération des levures dans les urines. Revue de la littérature et résultats préliminaires d'une enquête multicentrique réalisée dans 15 centres hospitaliers universitaires. Ann Fr Anesth Reanim 2001; 20: 400-06.
173. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379-90.
174. Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J 2000; 19: 822-27.
175. Miller PJ, Wenzel RP. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections. J Infect Dis 1987; 156: 471-77.
176. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections. A six year validated, population-based model. Clin Infect Dis 1997; 24: 1068-78.
177. Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 2002; 19: 846-50.